key: cord-1014324-8m0ywoxv
authors: Basse, Clémence; Diakite, Sarah; Servois, Vincent; Frelaut, Maxime; Noret, Aurélien; Bellesoeur, Audrey; Moreau, Pauline; Massiani, Marie-Ange; Bouyer, Anne-Sophie; Vuagnat, Perrine; Malak, Sandra; Bidard, François-Clément; Vanjak, Dominique; Kriegel, Irène; Burnod, Alexis; Bilger, Geoffroy; Ramtohul, Toulsie; Dhonneur, Gilles; Bouleuc, Carole; Cassoux, Nathalie; Paoletti, Xavier; Bozec, Laurence; Cottu, Paul
title: Characteristics and outcome of SARS-CoV-2 infection in cancer patients
date: 2020-10-09
journal: JNCI Cancer Spectr
DOI: 10.1093/jncics/pkaa090
sha: a52d09e09747287c112db6a9d317e0cc3847a168
doc_id: 1014324
cord_uid: 8m0ywoxv

BACKGROUND: Concerns have emerged about the higher risk of fatal COVID-19 in cancer patients. In this paper, we review the experience of a comprehensive cancer center. METHODS: A prospective registry was set up at Institut Curie at the beginning of the COVID-19 pandemic. All cancer patients with suspected or proven COVID-19 were entered and actively followed for 28 days. RESULTS: Among 9,842 patients treated at Institut Curie between March 13 and May 1, 2020, 141 (1.4%) were diagnosed with COVID-19, based on RT-PCR testing and/or CT-scan. In line with our case-mix, breast cancer (40.4%) was the most common tumor type, followed by hematological and lung malignancies. Patients with active cancer therapy or/and advanced cancer accounted for 87.9% and 68.9% of patients, respectively. At diagnosis, 78.7% of patients had COVID-19 related symptoms, with an extent of lung parenchyma involvement inferior to 50% in 95.8% of patients. Blood count variations and C-reactive protein elevation were the most common laboratory abnormalities. Antibiotics and antiviral agents were administered in 48.2% and 6.4% of patients, respectively. At the time of analysis, 26 patients (18.4%) have died from COVID-19, and 100 (70.9%) were cured. Independent prognostic factors at the time of COVID-19 diagnosis associated with death or intensive care unit admission were extent of COVID-19 pneumonia and decreased O(2) saturation. CONCLUSIONS: COVID-19 incidence and presentation in cancer patients appear to be very similar to those in the general population. The outcome of COVID-19 is primarily driven by the initial severity of infection rather than patient or cancer characteristics.

Since December 2019, the world has been faced with the emergence of Coronavirus Disease 2019 , caused by a novel beta-coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1 . The first cases of pneumonia were reported in Wuhan City, China, in December 2019 2 and were rapidly followed by worldwide dissemination. The World Health Organization (WHO) consequently declared COVID-19 (also called SARS-Cov-2 infection) a public health emergency of international concern 3 . COVID-19 has now affected more than four million people all over the world and has already been responsible for more than 250,000 deaths 4 . France has the 6 th highest number of cases of COVID-19 in the world, with almost 170,000 confirmed cases and more than 29,000 deaths 5 . The Paris area (Ile-de-France) is the epicenter of the epidemic in France 6 .

Cancer patients could represent a high-risk population in this global crisis. Based on a series of 44,672 confirmed cases in China, Wu et al. reported a 2.3% death rate in the general population versus 5.6% among cancer patients 7 . Several studies have simultaneously reported that pre-existing comorbidities (including cancer) constitute a risk factor associated with severe COVID-19 infection and ICU admission 8, 9 . COVID-19 appears to be more frequent among cancer patients, with an overrepresentation of cancer patients in the confirmed COVID-19 population compared to the general population in China 10, 11 . Initial retrospective cohorts of cancer patients with COVID-19 in China were characterized by a high rate of severe presentation (39% to 54% of cases) and a high mortality rate (13.5% to 29%) 11, 12 . However, more recent Chinese reports on hospitalized cancer patients have shown that the average mortality rate of COVID-19 among cancer patients was closer to 5-10% 13, 14 , and that patients with lung cancer or lung metastases were more prone to die from COVID-19 13 . A report from New York City suggested that only cancer patients younger than 50 were at higher risk of death when in intensive care unit 15 . The United Kingdom National Health Service reported a very weak association between cancer and the risk of dying from COVID-19 16 . Altogether, these cohorts 5 appeared to be heavily biased as they only included hospitalized patients and were therefore unlikely to reflect the real clinical outcome of COVID-19 in cancer patients.

The first proven case of COVID-19 in France was reported on January 24, 2020. The French hospital emergency response plan ("Plan Blanc") and a nation-wide lockdown were implemented on March 6, 2020. Institut Curie is a prominent comprehensive cancer center with three sites in Paris, Saint Cloud and Orsay (Supplementary Figure 1) . In view of the urgent need for more data on COVID-19 in cancer patients, we set up an institutional registry at the very beginning of the pandemic in France in order to more accurately determine the incidence of the disease and understand the outcomes in this fragile population, as well as identify specific risk factors for poor outcome. We prospectively registered all patients with confirmed or highly suspected COVID-19, including ambulatory patients with specific follow-up. From March 13 to May 1, 2020, 9,842 cancer patients were referred at one of the Institut Curie facilities, of whom 7,833 patients were receiving active therapy for any type of cancer, including breast cancer (50%), lung cancer (8%), gynecological cancer (8%), gastrointestinal cancer (7%), eye cancer (6%), head and neck cancer (6%), urological cancer (6%), hematological malignancy (5%) and sarcoma (5%). In this paper, we report the clinical characteristics and outcomes of SARS-CoV-2-infected patients treated or followed for cancer at Institut Curie, as of June 15, 2020.

An institutional database was implemented to prospectively collect information concerning cancer patients treated or followed at Institut Curie with suspected or confirmed SARS-CoV-2 virus infection. This registry was approved by the Institut Curie Institutional Review Board (IRB). No documentation or informed consent was required according to French regulations, as this study was strictly observational. Redcap® software was used as data repository. Starting on March 13, we consecutively registered patients with symptoms suggestive of COVID-19, and/or confirmed COVID-6 19 by nasopharyngeal swab RT-PCR, and/or images suggestive of COVID-19 on chest CT scan. Files of requests for RT-PCR were cross-checked to track possible missing patients. The design and reporting of this case-cohort study strictly complied with STROBE guidelines 17 .

The main data recorded were as follows: cancer history (age, sex, primary tumor site, localized or advanced tumor); current cancer treatment intent according to 3 categories (curative intent for adjuvant/neoadjuvant/early-stage treatment, disease control when active cancer treatment was administered for advanced cancer, and palliative phase); COVID-19 features (symptoms, nasopharyngeal swab RT-PCR result, when performed, suggestive chest CT scan images, when performed, laboratory parameters); COVID-19 severity (ambulatory patients, hospitalization, transfer to intensive care unit (ICU), COVID-19-or cancer-related death); consequences on current cancer treatment (delayed, canceled, modified). Comorbidities and comedications were also collected.

Patients who received noninvasive respiratory support in conventional hospitalization wards were considered to be hospitalized patients and not as ICU patients. Treatments specifically administered for COVID-19 were also recorded. Systematic medical follow-up was performed at day 7, day 14 and day 28 after inclusion in the registry. Ethnic group analyses are not allowed per French regulations.

From March 13, 2020, a systematic screening comprising a questionnaire and systematic body temperature check was implemented at entrance of all our facilities. According to national guidelines, SARS-CoV-2 RNA testing on nasopharyngeal swab (RT-PCR testing) was initially restricted to healthcare workers and severely ill patients 18 . Tests became more readily available (upon prescription) after March 25, and patients with COVID-19 symptoms were then tested for SARS-CoV-2 RNA whenever possible. SARS-CoV-2 RNA testing also became mandatory for all patients, even asymptomatic, scheduled for surgery at Institut Curie. Cancer care, imaging and laboratory assessments are detailed in Supplementary Methods.

Registry inclusion criteria were: patients either systematically screened for SARS-CoV-2 infection, or currently under treatment or surveillance at the Institut Curie for a solid tumor or hematological malignancy, presenting any symptom of COVID-19, or with confirmed COVID-19 by nasopharyngeal swab RT-PCR, or presenting chest CT scan images suggestive of COVID-19. Only patients with positive imaging and/or positive RT-PCR testing were considered positive for COVID-19

for the present analysis, regardless of their symptoms.

The primary objectives of the study were to evaluate the incidence of COVID-19 in Institut Curie patients and describe the clinical presentation, management and outcome of COVID-19 during the 28 days following onset of the first symptoms. Secondary objectives were to evaluate the impact of COVID-19 on cancer care, and factors associated with COVID-19 severity, such as concomitant treatments or comorbidities.

Descriptive statistics were reported in all COVID patients and in the subgroup with both positive RT-PCR and chest CT-scan. Laboratory measurements at diagnosis were compared to the reference value measured during the two precedent months with paired Student tests. The main clinical outcome was defined as death due to COVID-19 and/or ICU admission during follow-up within 6 weeks post diagnosis. As 28-days follow-up was obtained in all but 4 patients, the outcome was treated as binary. Univariate and multivariate prognostic factor analysis was performed using a logistic model and the Wald statistics for tests of parameters. For the multivariate analysis, a backward selection model was applied starting from all variables statistically significant at the 10% level in the univariate analysis and with less than 10% of missing data. Sensitivity analyses were performed on the prognostic factors for death alone and for time to worsening (ICU or death) using log-rank test and semi-parametric model after checking the proportional hazard assumption. All analyses were two-sided and performed with SAS v9.4 software. A P value of less than .05 was considered statistically significant. Other less common symptoms are shown in Table 1 . A total of 14 COVID-19 patients had been identified through the systematic screening before initiation of treatment. They had either no symptoms (n=10) or non-specific symptoms such as fever pain and fatigue (n=3); one had pulmonary distress. Suspicious imaging was found in two cases. Chemotherapy was delayed or modified in four of the 5 patients with an indication of chemotherapy. Surgery was delayed in 7 of the 8 patients with planned intervention. One of the 14 patients, who had gastro-esophagus disease and lung metastasis and had more than 3 lines of prior treatments, was hospitalized and died of complications possibly related to the COVID-19. All other patients recovered without admission to ICU.

Baseline chest CT scan findings, available for 80 patients, are described according to the extent of pulmonary parenchyma COVID-19-related alterations and clinical findings. The extent of parenchymal disease appeared to be relatively independent of the underlying patient or cancer key characteristics such as disease site or stage (Figure 2A ), comorbidities and co-medications ( Figure   2B ), or mode of COVID-19 diagnosis ( Figure 2C) Table 2 . We observed statistically significant, although clinically meaningless, differences in blood counts obtained in the same patients before and after SARS-Cov-2 infection. Statistically significant elevation of baseline serum C-reactive protein was recorded in 35 evaluable patients.

Patients were either discharged home (64.2%), or hospitalized (35.8%) depending on the severity of the symptoms. Antibiotics were prescribed in 48.2% of patients according to local guidelines. Antiviral drugs were administered in selected cases (6.4%) after a thorough review of the patient's medical history (Supplementary Table 3 ). Most patients stayed at home and remained asymptomatic or very slightly symptomatic between baseline and Day 28 ( Figure 3 ). However, 11 (7.8%) patients were transferred to the intensive care unit at some time during the course of the disease and, at the time of analysis, 26 patients (18.4%) had died from COVID-19, 4 (2.8%) had died from terminal cancer, 11 (7.8%) were recovering and 100 (70.9%) were cured. Lung cancers had the worst outcome (n=6 i.e. 23.1% of all deaths) followed by hematological malignancies (n=5, 19.2%), breast (n=5, 19.2%) and gynecological cancers (n=2, 7.7%). Twenty patients (76.9% of deceased patients) had received more than 3 lines of treatment for metastatic disease. The place of death was home (1), Institut Curie or other hospitals (12 and 8 respectively) and was missing for five patients.

A total of 35 patients had poor outcome (transfer to ICU or death). On univariate analysis (Table 3) , factors related to patient (Age >70, male gender), cancer (non-breast cancer, palliative setting), or SARS-CoV-2 infection (pulmonary symptoms, extent of radiological signs of pneumonia)

were statistically significantly associated with an increased risk of poor outcome. The final model of the multivariate analysis is provided in the same Table 3 . A particularly interesting finding on multivariate analysis was that only a baseline decrease in O2 saturation and the extent of radiological signs of lung damage remained predictors of death and/or ICU admission, with odds ratios (OR) of 6.71 (95% CI: 1.40 to 30.10) and 2.48 (95% CI: 1.29 to 4.79), respectively. The ORs for age (>70) and non-breast cancer were similar on univariate and multivariate analyses, but were no longer statistically significant. Sensitivity analyses of the risk of death alone and for the time to death or ICU admission provided the same statistically significant associations.

Based on individual assessment, chemotherapy, targeted therapy or immune checkpoint inhibitor therapy were delayed or stopped in 68.2%, 66.8% and 83.1% of COVID-19 cases, respectively. Planned surgical procedures were postponed in 78.6% of cases. Ongoing radiation therapy was delayed or canceled in 69.4% of cases. Elective surgery was rescheduled after a mean of 3 weeks (15 days to 6 weeks).

The COVID-19 pandemic has and continues to have a dramatic impact on health care systems worldwide. Cancer patients potentially represent one of the most vulnerable patient populations, and continuously updated data on how COVID-19 affects cancer care are essential. To the best of our knowledge, we report the first comprehensive prospective cohort of cancer patients, not confined to hospitalized patients, but also including outpatients with systematic and dedicated follow-up. We report three types of results.

Firstly, with 141 patients with COVID-19 observed during the period from March 13 to May 1, the minimum incidence rate of SARS-CoV-2 infection in the overall cohort of patients treated at Institut Curie during this period was 1.4%, (or 1.7% when only considering patients with active cancer treatment). Although this incidence rate is potentially underestimated, it is not higher than the 5.7% rate estimated for the whole French population during the same period with the same diagnostic guidelines, i.e. clinical screening, RT-PCR on naso-pharyngeal swabs and chest CT scan 19 . Of note, strict distancing measures had been implemented in France by mid-March. We also implemented a distant warning system for all our patients, including online messages, systematic text messaging and emails warnings and recommendations. Furthermore, the proportion of infected people in the Paris area ("Ile-de-France") in which the Institut Curie facilities are located (Supplementary Figure 1) is estimated to be 12.3% 19 , clearly suggesting that cancer patients, as a whole, are not more prone to SARS-CoV-2 infection than the general population when strict lockdown measures are implemented.

Secondly, the clinical features of COVID-19 in cancer patients appear to be very similar ( Table   1 , Figure 2 ) to those observed in the general population 7, 8, 12 . The vast majority of patients were symptom-free and had been discharged home by Day 28 (Figure 3) , and no specific radiological observed. Furthermore, the mortality rate observed in our prospective cohort (19%) was also similar to that reported in the general population (up to 20%) 20 , suggesting that the population of cancer patients presents a similar risk of dying from COVID-19 to that of the general population, in contrast with the results of several early retrospective studies 9, 11, 12, 15 . This in line with the NHS report showing a slight increase of dying from COVID-19 limited to inpatients with recent diagnosis of cancer 16 , and with the recent US report suggesting that risk of death is mostly due to general risk factors and some types of cancer such hematological malignancies 21 21 . Among them, 66% of patients had a performance status of 0 or 1 (compared to 50.6% in our population); 45% of patients presented remission or no evidence of disease, 32% has stable disease and 22% had a progressive/metastatic disease (compared to 31.1% with localized/controlled disease and 68.9% of metastatic disease in our cohort). The general health state of patients in our cohort was more fragile which may explain this difference. Another of the 13 most striking observations in our cohort is that, when using ICU admission and/or death as a relevant clinical endpoint, COVID-19-related characteristics clearly appeared to be the most powerful predictors of poor outcome, as partly reported in several retrospective general cohorts 2, 9, 12 . We observed a potential trend for a higher risk of death/ICU admission in older patients, and in patients with non-breast cancer (mostly lung and hematological malignancies) or in the palliative setting.

Inpatients diagnosed with COVID-19 had not a higher risk of death from the infection. Several hypotheses could also explain the lower than expected rate of severe COVID-19. In this study, in addition to hospitalized patients, we also included ambulatory patients, corresponding to patients with milder symptoms and a more favorable disease outcome. Of note, 24.1% of the patients of this cohort received anticoagulants, which may have prevented thromboembolic complications 22 . We did not observe any case of cytokine storm syndrome 23 , which may have been prevented by pre-existing inflammatory state 24 , or conversely immune exhaustion 25 .

Thirdly, we also prospectively recorded the impact of COVID-19 on cancer care. More than two-thirds of scheduled cancer treatments were canceled, postponed or statistically significantly modified. In a separate study, we evaluated that first consultations for breast cancer decreased by 34% compared to the same period in 2019 26 . As highlighted by many authors, the COVID-19 pandemic will very likely have a major collateral impact on cancer outcome in the next months to come [27] [28] [29] [30] [31] , while placing the cancer workforce under a considerable strain 32 .

There are limitations to this study. Access to RT-PCR tests differed between the beginning and the end of the cohort registration period, due to limited test availability at the beginning of the registration period (Supplemental Figure 2) . It is far too early to evaluate the actual cancer outcome of cancer patients in the COVID-19 era. We are also aware that breast cancer patients may be overrepresented in our cohort, which could contribute to the overall good prognosis of SARS-CoV-2 infection observed in this study. However, our practice is similar to that of other comprehensive cancer centers, and our experience can therefore provide useful information in this specific context. This registry needs to be continued in order to provide more extensive and more robust data.

In summary, early reports on cancer and COVID-19, mostly based on hospitalized cancer patients, tended to suggest that cancer patients were more prone to suffer from SARS-CoV-2 infection and experienced a higher mortality rate. Special attention must be paid to patients with lung cancer and hematological malignancies. However, risk factors for COVID-19 mortality are mostly infection-related rather than cancer-related. Overall, our findings from a large prospective cohort of representative cancer patients and treatments, including ambulatory, non-hospitalized patients, strongly suggest that COVID-19 is neither more frequent nor more fatal in cancer patients as a whole.

A simple baseline clinical assessment combining O2 saturation measure and a chest CT scan clearly identifies patients at risk of poor outcome and should be widely recommended in cancer patients with suspected COVID-19. As of April 28, a systematic serological testing is now performed in all patients (those included in the present cohort as well as new patients). We believe that the data presented here, combined with more accurate epidemiological data based on longer follow-up and generalized antibody testing, will pave the way to safer and individualized care and lockdown ease for cancer patients in the COVID-19 era.

Paris-Saclay (no grant number applicable).

The role of the funder : The funders had no role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication.

The authors declare that they have no competing interests. 

The data underlying this article cannot be shared publicly due to current French HIPAA regulations (birthdate, admission date, discharge date, date of death). Data will be shared on reasonable request to the corresponding author. 

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Clinical features of patients infected with

The Lancet

WHO Coronavirus Disease outbreak news

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol

Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov

Clinical determinants for fatality of 44,672 patients with COVID-19

Do Patients with Cancer Have a Poorer Prognosis of COVID-19? An Experience

OpenSAFELY: Factors Associated with COVID-19-Related Hospital Death in the Linked Electronic Health Records of 17 Million Adult NHS Patients. Epidemiology

A Review of Published Analyses of Case-Cohort Studies and Recommendations for Future Reporting

Estimating the Burden of SARS-CoV-2 in France. Epidemiology

Real estimates of mortality following COVID-19 infection

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet

Cancer-related inflammation and treatment effectiveness

Molecular and cellular insights into T cell exhaustion

Impact de l'épidémie de COVID-19 sur les demandes de prise en charge initiale pour cancer du sein

Collateral Damage: The Impact on Cancer Outcomes of the COVID-19 Pandemic

Covid-19: Cancer mortality could rise at least 20% because of pandemic, study finds

Caring for Patients With Cancer During the COVID-19 Outbreak in Italy

Managing COVID-19 in the oncology clinic and avoiding the distraction effect

Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands

COVID-19: impact on cancer workforce and delivery of care

a reference =laboratory test results obtained no more than 2 months before inclusion in the registry. CRP: C-reactive protein. b Paired two-sided Student test